Gabriela Loperena Oropeza, MD
Endocrinology, Diabetes & Metabolism · Tacoma, WANPI 1548452162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 664 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,246 and has fallen 91.3% since, to $281 in 2025.
Across 664 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Medtronic$2K
- Amgen$1K
- Boehringer Ingelheim$997
- Sanofi-aventis U.S. LLC$714
- AstraZeneca$568
- plus $5K from 31 others
What the payments were for
- Travel & lodging$5635%
- Food & beverage$10,84294%
- Education$811%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 173 | $1,852 |
| Medtronic(2 entities) | 42 | $1,509 |
| Amgen(2 entities) | 51 | $1,251 |
| Boehringer Ingelheim | 53 | $997 |
| Sanofi-aventis U.S. LLC | 47 | $714 |
| AstraZeneca(2 entities) | 33 | $568 |
| Lilly USA, LLC | 42 | $537 |
| Tandem Diabetes Care, Inc. | 8 | $357 |
| Dexcom, Inc. | 14 | $355 |
| Bayer | 12 | $299 |
| Corcept Therapeutics | 13 | $284 |
| Johnson & Johnson | 27 | $278 |
| Antares Pharma, Inc. | 15 | $274 |
| Xeris Pharmaceuticals, Inc. | 13 | $233 |
| Amryt Pharma Holdings Ltd | 8 | $203 |
| Merck | 22 | $192 |
| Novartis | 9 | $190 |
| AbbVie | 13 | $173 |
| Insulet Corporation | 8 | $154 |
| Mannkind Corporation | 12 | $152 |
| Abbott | 6 | $127 |
| Recordati_rare_diseases_inc. | 4 | $120 |
| Radius Health, Inc. | 7 | $116 |
| IBSA Pharma Inc. | 6 | $115 |
| Amarin Pharma, Inc. | 6 | $109 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| Lifescan, Inc. | 4 | $74 |
| Ascensia Diabetes Care US Inc. | 2 | $42 |
| BETA Bionics, Inc. | 2 | $35 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Pfizer | 2 | $27 |
| Companion Medical, Inc. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $16 |
| Aegerion Pharmaceuticals, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$528
- Macrilen$275
- EVENITY$233
- Ozempic$225
- t:slim X2 Insulin Pump with Control-IQ$133
- Minimed 670G System$125
- TEPEZZA$125
How this compares
$11,545 in reported general payments places this provider in the 85th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $146,930 |
| JardianceEmpagliflozin | 53 | $71,198 |
| MounjaroTirzepatide | 53 | $69,879 |
| TrulicityDulaglutide | 16 | $40,514 |
| GenotropinSomatropin | 11 | $40,259 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $33,948 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 72 | $31,433 |
| FarxigaDapagliflozin Propanediol | 25 | $31,325 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $29,207 |
| JanuviaSitagliptin Phosphate | 20 | $28,298 |
| Bydureon BciseExenatide Microspheres | 17 | $26,343 |
| Humalog Kwikpen U-100Insulin Lispro | 45 | $16,647 |
| TradjentaLinagliptin | 19 | $15,763 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $14,590 |
| SynthroidLevothyroxine Sodium | 147 | $14,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,852 | $158,817111 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $537 | $120,11282 claims |
| Boehringer IngelheimJardiance, Tradjenta | $997 | $86,96172 claims |
| PfizerGenotropin | $27 | $40,25911 claims |
| AstraZenecaFarxiga | $568 | $31,32525 claims |
| MerckJanuvia | $192 | $28,29820 claims |
| AbbVieSynthroid | $173 | $14,083147 claims |
| Sanofi-aventis U.S. LLCLantus | $714 | $6,26620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Tacoma
- Ronald GrafTacoma$13K
- Ayesha JameelTacoma$9K
- Rebecca OverTacoma$6K
- Rani KulkarniTacoma$3K
- Qin OuyangTacoma$2K
- Zhiyu WangTacoma$2K
- Dali ChenTacoma$2K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.